1763 — China Isotope & Radiation Balance Sheet
0.000.00%
- HK$3.68bn
- HK$6.54bn
- CNY7.57bn
- 33
- 76
- 88
- 76
Annual balance sheet for China Isotope & Radiation, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2,556 | 2,714 | 2,929 | 2,873 | 2,626 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,369 | 2,851 | 3,522 | 3,896 | 4,981 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 5,771 | 6,657 | 7,544 | 8,194 | 8,918 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2,210 | 2,513 | 2,940 | 3,601 | 4,328 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 9,185 | 10,474 | 11,790 | 13,192 | 14,767 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2,772 | 3,972 | 4,031 | 4,254 | 5,023 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 5,294 | 6,295 | 7,321 | 8,498 | 9,762 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 3,891 | 4,179 | 4,469 | 4,693 | 5,005 |
Total Liabilities & Shareholders' Equity | 9,185 | 10,474 | 11,790 | 13,192 | 14,767 |
Total Common Shares Outstanding |